2',6'-dichloro-3-methyl-2,4'-bipyridine | 749257-58-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2',6'-dichloro-3-methyl-2,4'-bipyridine
• 英文别名: 2,6-Dichloro-4-(3-methylpyridin-2-yl)pyridine
• CAS: 749257-58-7
• 化学式: C₁₁H₈Cl₂N₂
• 分子量: 239.104
• InChiKey: IZLSDKYCTUFURN-UHFFFAOYSA-N

物化性质

• 沸点：
  345.7±37.0 °C(Predicted)
• 密度：
  1.318±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2',6'-dichloro-3-methyl-2,4'-bipyridine 在 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 19.0h， 生成 (3R)-4-[6-(5-fluoro-1H-pyrrolo[2,3-c]pyridin-4-yl)-4-(3-methylpyridin-2-yl)pyridin-2-yl]-3-methylmorpholine
  参考文献：
  名称：

  EP4159734

  摘要：

  公开号：
• 作为产物：
  描述：

  2,6-二氯吡啶 、 (3-methylpyridin-2-yl)(phenyl)(p-tolyl)sulfonium trifluoromethanesulfonate 在 2,2,6,6-tetramethylpiperidinylmagnesium chloride lithium chloride complex 作用下， 以 四氢呋喃 为溶剂， 反应 2.17h， 以64%的产率得到2',6'-dichloro-3-methyl-2,4'-bipyridine
  参考文献：
  名称：

  使用格氏试剂和吡啶基锍盐合成双杂芳基化合物

  摘要：

  本文报道了格氏试剂与吡啶基锍盐的配体偶联反应。该方法具有广泛的官能团耐受性，能够形成双杂环键，包括 2,4'-、2,3'-和 2,2'-联吡啶，以及与嘧啶、吡嗪、异恶唑连接的吡啶，和苯并噻吩。该方法成功地应用于天然产物 caerulomycin A 和 E 的合成。

  DOI：

  10.1021/acs.orglett.1c03379

文献信息

• [EN] SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN<br/>[FR] AMINO-HETEROCYCLES SUBSTITUES EN TANT QU'ANTAGONISTES DU VR-1 POUR TRAITER LA DOULEUR
  申请人：MERCK SHARP & DOHME

  公开号：WO2004074290A1

  公开（公告）日：2004-09-02

  The present invention provides compounds of formula I: in which: one of T1 and T4 is N and the other is C; T2 and T3 are independently N or C(CH2)nR2; X, Y and Z are independently N or C(CH2)nR3; R1 is Ar1 or R1 is C1-6alkyl optionally substituted with one or two groups Ar1; Ar1 is an optionally substituted cyclohexyl, piperidinyl, piperazinyl, morpholinyl, adamantyl, phenyl, naphthyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six-or five-membered heteroaromatic ring as defined above; Ar is an optionally substituted phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar being optionally substituted by one, two or three groups chosen from halogen, CF3, OCF3, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, nitro, cyano, isonitrile, hydroxy, C1-6alkoxy, C1-6alkylthio, -NR6R7, -CONR6R7, -COH, CO2H, C1-6alkoxycarbonyl, haloC1-6alkyl, hydroxyC1-6alkyl, aminoC1-6alkyl, C1-6alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, optionally substituted by C1-6alkyl, halogen, amino, hydroxy or cyano; or a pharmaceutically acceptable salt thereof as a VR-1 ligand; pharmaceutical compositions comprising it; its use in therapy; use of it in the manufacture of a medicament to treat pain; and methods of treating subjects suffering from pain.

  本发明提供了式I的化合物：其中：T1和T4中的一个是N，另一个是C; T2和T3独立地是N或C（CH2）nR2; X，Y和Z独立地是N或C（ ）nR3; R1是Ar1或R1是C1-6烷基，可选地取代一个或两个Ar1基团; Ar1是可选取代的环己基，哌啶基，哌嗪基，吗啉基，金刚烷基，苯基，萘基，一个六元杂环芳香环，其中含有一个，两个或三个氮原子，一个五元杂环芳香环，其中选择了一个，两个，三个或四个杂原子从O，N和S中选择，最多只有一个O或S原子存在，或一个九元或十元的双环杂芳香环，其中苯基或上述定义的六元杂环芳香环与上述定义的六元或五元杂环芳香环融合; Ar是可选取代的苯基，一个含有一个，两个或三个氮原子的六元杂环芳香环或一个含有一个，两个，三个或四个从O，N和S中选择的杂原子的五元杂环芳香环，最多只有一个杂原子是O或S，Ar可选地取代由卤素，CF3，O ，C1-6烷基，C2-6烯基，C2-6炔基，硝基，氰基，异腈基，羟基，C1-6烷氧基，C1-6烷基硫基，-NR6R7，-CONR6R7，-COH，CO2H，C1-6烷氧羰基，卤代C1-6烷基，羟基C1-6烷基，氨基C1-6烷基，C1-6烷基羰基和一个含有一个，两个，三个或四个从O，N和S中选择的杂原子的五元杂环芳香环，最多只有一个杂原子是O或S，可选地被C1-6烷基，卤素，氨基，羟基或氰基取代;或其药学上可接受的盐作为VR-1配体;包含它的制药组合物;其在治疗中的用途;将其用于制造治疗疼痛的药物;以及治疗患有疼痛的受试者的方法。
• Substituted amino heterocycles as vr-1 antagonists for treating pain
  申请人：Brown Elizabeth Rebecca

  公开号：US20060154930A1

  公开（公告）日：2006-07-13

  The present invention provides compounds of formula I: in which: one of T 1 and T 4 is N and the other is C; T 2 and T 3 are independently N or C(CH 2 ) n R 2 ; X, Y and Z are independently N or C(CH 2 ) n R 3 ; R 1 is Ar 1 or R 1 is C 1-6 alkyl optionally substituted with one or two groups Ar1; Ar1 is an optionally substituted cyclohexyl, piperidinyl, piperazinyl, morpholinyl, adamantyl, phenyl, naphthyl, a six membered heteroaromatic ring containing one, two or three nitrogen atoms, a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one O or S atom being present, or a nine- or ten-membered bicyclic heteroaromatic ring in which phenyl or a six-membered heteroaromatic ring as defined above is fused to a six- or five-membered heteroaromatic ring as defined above; Ar is an optionally substituted phenyl, a six-membered heteroaromatic ring containing one, two or three nitrogen atoms or a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, Ar being optionally substituted by one, two or three groups chosen from halogen, CF 3 , OCF 3 , C 1-6 -alkyl, C 2-6 alkenyl, C 2-6 alkynyl, nitro, cyano, isonitrile, hydroxy, C 1-6 alkoxy, C 1-6 alkylthio, —NR 6 R 7 , —CONR 6 R 7 , —COH, CO 2 H, C 1-6 alkoxycarbonyl, haloC 1-4 alkyl, hydroxyC 1-6 alkyl, aminoC 1-6 alkyl, C 1-4 alkylcarbonyl and a five-membered heteroaromatic ring containing one, two, three or four heteroatoms chosen from O, N and S, at most one heteroatom being O or S, optionally substituted by C 1-6 alkyl, halogen, amino, hydroxy or cyano; or a pharmaceutically acceptable salt thereof as a VR-1 ligand; pharmaceutical compositions comprising it; its use in therapy; use of it in the manufacture of a medicament to treat pain; and methods of treating subjects suffering from pain.

  本发明提供了公式I的化合物：其中：T1和T4中的一个是N，另一个是C; T2和T3分别是N或C（CH2）nR2; X，Y和Z分别是N或C（ ）nR3; R1是Ar1或R1是C1-6烷基，可选地取代一个或两个Ar1基团; Ar1是可选地取代的环己基，哌啶基，哌嗪基，吗啉基，金刚烷基，苯基，萘基，含有一个，两个或三个氮原子的六元杂环芳烃环，含有一，两，三或四个O，N和S杂原子的五元杂环芳烃环，最多只有一个O或S原子存在，或者是将苯基或上述定义的六元杂环芳烃环与上述定义的六元或五元杂环芳烃环融合而成的九元或十元双环杂环芳烃环; Ar是可选地取代的苯基，含有一个，两个或三个氮原子的六元杂环芳烃环或含有一，两个，三个或四个O，N和S杂原子的五元杂环芳烃环，最多只有一个杂原子为O或S，Ar可被一，两或三个由卤素，CF3，O ，C1-6烷基，C2-6烯基，C2-6炔基，硝基，氰基，异腈基，羟基，C1-6烷氧基，C1-6烷基硫基，-NR6R7，-CONR6R7，-COH，CO2H，C1-6烷氧基羰基，卤代C1-4烷基，羟基C1-6烷基，氨基C1-6烷基，C1-4烷基羰基和含有一，两个，三个或四个O，N和S杂原子的五元杂环芳烃环取代的基团取代;或其药学上可接受的盐作为VR-1配体;包含它的制药组合物;其在治疗中的应用;将其用于制造治疗疼痛的药物;以及治疗疼痛患者的方法。
• [EN] FLUOROPYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE FLUOROPYRROLOPYRIDINE ET SON APPLICATION<br/>[ZH] 氟代吡咯并吡啶类化合物及其应用
  申请人：SHENZHEN LIFE FOUNTAIN BIOTECH CO LTD

  公开号：WO2021238999A1

  公开（公告）日：2021-12-02

  本发明公开了一类氟代吡咯并吡啶类化合物。具体公开了式(Ⅱ)所示化合物、其异构体或其药学上可接受的盐。
• SUBSTITUTED AMINO HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP1597261A1

  公开（公告）日：2005-11-23